A potential epigenetic marker mediating serum folate and vitamin B12 levels contributes to the risk of ischemic stroke by Loo, Keat Wei et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Loo, Keat Wei, Griffiths, Lyn R., Sutherland, Heidi, Haupt, Larisa M., &
Bhaskar, Shalini
(2015)
A potential epigenetic marker mediating serum folate and vitamin B12 lev-
els contributes to ischemic stroke risk.
BioMed Research International, 2015(167976).
This file was downloaded from: http://eprints.qut.edu.au/90714/
c© Copyright 2015 Loo KeatWei et al.
This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and re-
production in any medium, provided the original work is properly cited.
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
http://doi.org/10.1155/2015/167976
A potential epigenetic marker mediating serum folate and vitamin B12 levels contributes 
to ischemic stroke risk 
 
Keat Wei Loo1,2, Lyn R Griffiths2, Heidi Sutherland2, Larisa M Haupt2, Shalini Bhaskar3, 
Siew Hua Gan1 
 
1Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, Kubang 
Kerian, 16150, Kelantan, Malaysia. 
2Genomics Research Centre, Institute of Health and Biomedical Innovation Queensland 
University of Technology, Musk Ave, Kelvin Grove, QLD, 4059, Australia. 
3Medical Department, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. 
 
Abstract 
Background and Purpose 
Stroke is a multifactorial disease that may be associated with aberrant DNA methylation profiles. 
We investigated epigenetic dysregulation for the MTHFR gene among ischaemic stroke patients. 
Methods 
Cases (n=297) and controls (n=110) were recruited after obtaining signed written informed 
consent, following a screening process against the inclusion/exclusion criteria. Serum vitamin 
metabolites (folate, vitamin B12 and homocysteine) were determined using immunoassaysand 
methylation profiles for CpGs A and B in the MTHFR gene were determined using bisulfite-
pyrosequencing method.  
Results 
Methylation of MTHFR significantly increased the susceptibility risk for ischemic stroke. In 
particular, CpG A outperformed CpG B in mediating folate and vitamin B12 levels to increase 
ischemic stroke susceptibility risks by 4.73 fold. CpGs A and B were not associated with either 
serum homocysteine levels or ischemic stroke severity.  
Conclusion 
CpG A is a potential epigenetic marker in mediating serum folate and vitamin B12 to contribute to 
ischemic stroke.  
 
Introduction 
Stroke is a multifactorial disease with 90% of cases being classified as ischemic stroke while 
hemorrhagic stroke makes up the remaining (Matouk et al., 2012). Emerging lines of 
evidencehave suggested that aberrant DNA methylation may affect the vulnerability of central 
nervous system injury responses following ischemia (Qureshi and Mehler, 2010, Matouk et al., 
2012). Despite its active involvement in generating S-adenosylmethionine for the methylation 
process, to datethe methylation profiles of MTHFR have not been fully elucidated. We aim to 
investigate potential epigenetic dysregulation of the MTHFR gene in ischaemic stroke patients. 
 
Methods 
This study was approved by the Institutional Ethics Review Committee of Universiti Sains 
Malaysia (reference no: USMKK/PPP/JEPeM [231.1.(08)]) which complies with the Declaration 
of Helsinki. Signed written informed consent forms were obtained from each participant prior to 
their enrollments and subjects following screening against the inclusion and exclusion criteria 
(Supplementary Table 1, Supplementary Figure 1).   
 Fasting blood samples (6 ml) were collected in clot activator gel tube (Becton Dickinson) 
for the determination of serum vitamin metabolites (serum homocysteine, folate and vitamin B12 
levels). Serum homocysteine levels were determined using fluorescence polarization 
immunoassay (Architect ci8200 Abbott, Illinois) while serum folate and vitamin B12 levels were 
determined using competitive immunoassay of direct chemiluminescence technology 
respectively (ADVIA Centaur XP immunoassay system, Siemens Healthcare). Venous blood 
samples (2 mL) were collected for DNA methylation profiling. DNA extraction bisulphite 
treatment and PCR-pyrosequencing were performed to determine methylation levels of CpGs A 
and B (Supplementary Figure 2, Loo et al. unpublished data).  
Statistical analysis was performed using R packages version 3.0.3 (New Jersey, 
USA). The demographic characteristics of the study subjects were analyzed using t-test for 
continuous variables while chi-squared (χ²) test was used for categorical variables. Pearson 
correlation coefficient (r) was used to establish the correlation between methylation and serum 
vitamin metabolites. Logistic regression models were used to estimate the odds ratios (ORs) 
and 95% confidence intervals (CI) for determining possible high risk methylation profiles for 
ischemic stroke and its severity. Age, gender and serum vitamin metabolites were controlled in 
multivariate analysis.  
 
Results 
Cases and controls demonstrated similar age groupings (Table 1, all p>0.05) while CpG A 
demonstrated higher ratios of females amongst cases when compared to controls (Table 1, 
p<0.05). Correlation analysis demonstrated that the methylation levels in CpG A were positively 
correlated with serum folate (r=0.106, p=0.032) and vitamin B12 (r=0.114, p=0.022) levels but 
not with those in CpG B. Methylation profiles in both CpGs A and B were not significantly 
correlated with serum homocysteine levels. Following multivariate adjustment, CpG A 
methylation levels were shown to confer a significantly higher risk (by 4.73-fold) of ischemic 
stroke (95% CI 2.56-8.75, p<0.001). The susceptibility risk for CpG B levels was however non-
significantly (Table 2) associated with ischemic stroke risk. In addition, neitherCpG levels were 
significantly associated with ischemic stroke severity following multivariate analysis (Table 3, 
p>0.05).  
 
Discussion 
To our knowledge, this is the first study to investigate MTHFR methylation profiles among 
Asians ischemic stroke patients. Similar to most epidemiological studies utilising DNA from 
peripheral blood cells (Relton et al., 2012, Lin et al., 2014), our study supports the notion that 
DNA is an informative determinant for epigenetic variation especially when brain cells are 
inaccessible (Relton et al., 2012). We demonstrated that CpG A but not CpG B methylation 
levels were significantly associated with increasedsusceptibility risk for ischemic stroke. There is 
some support for a role of epigenetics in ischemic stroke risk but to most studies (Baccarelli et 
al 2010; Lin et al., 2014) have focued on increased susceptibility risk of ischemic stroke and 
long interspersed element-1 methylation.  
MTHFR methylation profiles at CpG A were shown to be associated with serum folate 
and vitamin B12 levels and also associated with thigher risks of ischemic stroke when compared 
to CpG B. Computational biology analysis have indicated that low density lysine 4 histone H3 tri-
methylation and incomplete RNA polymerase II in CpG B (as observed from our unpublished in 
silico data) may affect the transcriptional activity of MTHFR. Increased lysine 4 histone H3 
methylation is an epigenetic mark for euchromatin, often accompanied by the presence of RNA 
polymerase II to act as an active promoter (Majocchi et al., 2014).  
Several studies have demonstrated alink between vitamin metabolites and DNA 
methylation indicating the pertinent role of one carbon metabolism in modulating DNA 
methylation (Fernàndez-Roig et al., 2012; Batra and Devasagayam, 2012). One carbon 
metabolism has been reported to be the main channel for methyl group donation at cellular 
levels (Johansson et al., 2011) where a depletion of vitamin B12 or folate can reduce the 
bioavailability of S-adenosylmethionine (Batra and Devasagayam, 2012). Decreased 
bioavailability of S-adenosylmethionine can hamper the genome wide methylation process 
(Baccarelli et al., 2010) and favour the reduction of lysine 4 of histone H3 methylation (Batra 
and Devasagayam, 2012). 
Howeverwe have not established any correlation of MTHFR methylation with serum 
homocysteine levels suggesting that 1) an intergenic methylation of MTHFR may not play a 
major role in affecting the serum homocysteine levels or 2) serum homocysteine levels may not 
be an essential proxy for gene expression changes. In addition, the non-significant correlation 
may also explain the non-significant correlation between MTHFR methylation and ischemic 
stroke severity. This is supported by the fact that homocysteine is actively involved in oxidative 
stress events which can affect vascular structure (Pezzini et al., 2007) to worsen ischemic 
stroke severity (Okubadejo et al., 2008).  
A recent report on the association between hemi-methylated MTHFR gene with silenced 
MTHFR gene expression among end-stage renal disease patients (Ghattas et al., 2014), has 
suggested a significant role of MTHFR promoter methylation on its gene expression levels. 
Therefore, future studies which investigate the effects of MTHFR methylation on gene 
expression changes is warranted for a better understanding of the epigenetic mechanisms of 
MTHFR in mediating serum vitamin metabolites to contribute to ischemic stroke.  
 
Conclusion 
Methylation of MTHFR significantly increases susceptibility risk for ischemic stroke but does not 
affect ischemic stroke severity. MTHFR CpG A outperforms CpG B in mediating folate and 
vitamin B12 levels to increase ischemic stroke susceptibility by 4.73 fold; however, neither CpG 
level was correlated with serum homocysteine levels.  
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Supplementary Figure 1 An overview of the study design. 
 
Informed consent and screening against inclusion and exclusion criteria 
Controls (n=110) 
Controls (n=49) 
Cases (n=297) 
Cases (n=149) 
CpG A 
CpG B 
Supplementary Table 1 Inclusion and exclusion criteria for study subjects 
 Inclusion criteria Exclusion criteria 
Controls 1. Three generations of Malays 1. Confirmed to have medical illness that 
require treatments 
 2. Healthy subjects aging between 18 and 70 
years old. 
2. Having family history of stroke  
 3. Normal findings on medical history and 
physical examination 
3. Subjects on any form of vitamins B 
supplementation six months prior to the 
study 
   
Cases 1. Three generations of Malays 1. Participation in any on-going clinical trial 
study 
 2. Ischaemic stroke patients aged between 
18 and 70 
2. Subjects on any form of vitamins B 
supplementation six months prior to the 
study 
 3. Occlusion, stenosis and/or lesion 3. Intra-cerebral haemorrhage confirmed by 
confirmed by brain imaging (computerised 
tomography scan or magnetic resonance 
imaging) 
brain imaging (computerised tomography 
scan or magnetic resonance imaging) 
 4. Stroke severity assessment based on 
Modified Rankin Scale 
4. Having brain tumours or other forms of 
cancer 
 
 
Table 1 Demographic characteristic of study subjects 
 CpG A  CpG B  
Parameters Controls (n=110) Cases (n=297) Controls (n=49) Cases (n=149) 
Age (years) 52.74 ± 7.69 52.62 ± 8.83 51.12 ± 7.29 52.08 ± 8.21 
Gender (male:female) 1.16 1.83* 0.96 1.48 
 Values are the mean ± standard deviation from  t-test for continuous variables and χ² test for categorical variables. *p <0.05 versus 
controls.  
Table 2 Susceptible risk of DNA methylation on ischemic stroke 
 Crude Adjusted 
CpGs β 95% CI p value β 95% CI p valuea 
A 3.85 2.72-5.45 <0.001 4.73 2.56-8.75 <0.001 
B 1.38 1.08-1.77 0.011 0.90 0.56-1.45 NS 
Abbreviations: NS: not significant. 
aMultivariate analysis adjusted for age, genders and serum vitamin metabolites. 
 
 
Table 3 Influence of DNA methylation on ischemic stroke severity 
 Crude Adjusted 
CpGs β 95% CI p value β 95% CI p valuea 
A -0.09 -0.15 to 0.13 NS -0.02 -0.16 to 0.12 NS 
B 0.02 -0.25 to 0.31 NS 0.02 -0.71 to 0.85 NS 
Abbreviations: NS: not significant. 
aMultivariate analysis adjusted for age, genders and serum vitamin metabolites. 
 
